TP53 and non-small cell lung carcinoma: The RELAY study (25), a phase III trial, investigating the efficacy of ramucirumab plus erlotinib versus placebo plus erlotinib in EGFR-positive NSCLC patients, showed that patients with TP53 co-mutations at baseline benefited more from combination therapy in terms of PFS, regardless of exon 19del or exon 21 L858R mutations.